Keybanc Maintains Overweight on Regal Rexnord, Raises Price Target to $184
Keybanc analyst Jeffrey Hammond maintains Regal Rexnord (NYSE:RRX) with a Overweight and raises the price target from $172 to $184.
Benzinga’s Top Ratings Upgrades, Downgrades For December 1, 2022
Upgrades Northcoast Research upgraded the previous rating for SpartanNash Co (NASDAQ:SPTN) from Neutral to Buy. SpartanNash earned $0.55…
Wolfe Research Downgrades Regal Rexnord to Peer Perform
Wolfe Research analyst Nigel Coe downgrades Regal Rexnord (NYSE:RRX) from Outperform to Peer Perform.
Regal Rexnord Announces Successful First Phase Of Financing For Proposed Acquisition Of Altra
Regal Rexnord Corporation (NYSE:RRX) today announced that it has completed the first phase of financing for its proposed acquisition of Altra Industrial Motion Corp. ("Altra"), by successfully amending its
Regal Rexnord Corp. Raising Guidance Mid-Point By Revising 2022 Annual Guidance For Adj. EPS To A Range Of $10.35-$10.75 From $10.20-$10.80 And Revising GAAP EPS Guidance To A Range Of $7.15-$7.55 From $7.01-$7.61
Raising Guidance Mid-Point By Revising 2022 Annual Guidance For Adjusted EPS To A Range Of $10.35 To $10.75 From $10.20 To $10.80 And Revising GAAP
Regal Rexnord Q3 EPS $1.80, Sales $1.32B Beat $1.31B Estimate
Regal Rexnord (NYSE:RRX) reported quarterly earnings of $1.80 per share. The company reported quarterly sales of $1.32 billion which beat the analyst consensus estimate of $1.31 billion by 1.15 percent. This is a
Will Investors Notice Exciting Sign On Regal Rexnord’s Chart?
If history is any guide, there may be good fortune ahead for shares of Regal Rexnord (NYSE:RRX). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.
Expert Ratings for Regal Rexnord
Within the last quarter, Regal Rexnord (NYSE:RRX) has observed the following analyst ratings:
Keybanc Maintains Overweight on Regal Rexnord, Raises Price Target to $172
Keybanc analyst Jeffrey Hammond maintains Regal Rexnord (NYSE:RRX) with a Overweight and raises the price target from $155 to $172.